NewsRx

Search our medical news database

Junctional Epidermolysis Bullosa

LAMB3 Expression Ameliorates Symptoms Of Blistering Skin Disease

Published in Gene Therapy Weekly, June 21st, 2001

by Deborah W. Heinrich, PhD, staff medical writer - A new study holds promise for gene therapy treatment of the blistering skin disorder junctional epidermolysis bullosa (JEB).

P.B. Robbins and colleagues in the Program of Epithelial Biology at Stanford University School of Medicine in Stanford, California explained that skin blistering and an altered distribution of basement membrane zone proteins such as BPAG2, integrins beta4/beta1, and laminins alpha3/gamma2 observed in patients with JEB are a result of mutation in the laminin 5 beta 3 gene, LAMB3. They therefore hypothesized that wild type expression of LAMB in keratinocytes in these patients might ameliorate...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook